ARCHIVES

ASCO: Anastrozole Adds Treatment Option, But Tamoxifen Remains Standard

This article is from The Cancer Letter archive.

Vol. 28 No. 33 | September 13, 2002

Download PDF Visit The Full Archive

Related Articles

ACS Expresses Concern About “Fletcher Report” On Mammography

May 7, 1993

RRP Planning Dosimetry Center, Treatment Planning Projects

March 20, 1987

AVEO’s Tivozanib Sunk by Fundamental Flaw: Higher Overall Survival in the Control Arm

May 8, 2013

Groups Urge FDA To Take Action Against Tobacco Products

June 27, 2014

In Brief: Day, Foti Lead Coalition; Harkin Ends Campaigns; UT Southwestern Recieves $85 Mil. In Donations

March 13, 1992

In Brief: The Anatomy Of An Administrative Nightmare: How NIH Spent $518 Million In One Day

October 23, 1992